Publications by authors named "Dee Wynne"
Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab. Clinical data from a phase 1 trial with lumiliximab demonstrated an acceptable toxicity profile in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). We therefore pursued a phase 1/2 dose-escalation study of lumiliximab added to fludarabine, cyclophosphamide, and rituximab (FCR) in previously treated CLL patients.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the anti-CD23 antibody lumiliximab in patients with chronic lymphocytic leukemia (CLL) who had previously been treated.
- Patients received varying doses of lumiliximab over a set schedule, with no observed partial or complete responses but limited toxicity noted.
- Findings revealed that while lumiliximab was tolerated well and showed some biological activity, it didn't significantly reduce CD23 levels despite increases in soluble CD23 levels at higher doses.